Myriad Genetics (MYD) Stock Overview
A molecular diagnostics and precision medicine company, develops molecular tests. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
MYD Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Myriad Genetics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.58 |
| 52 Week High | US$7.10 |
| 52 Week Low | US$3.00 |
| Beta | 1.65 |
| 1 Month Change | -9.16% |
| 3 Month Change | 16.05% |
| 1 Year Change | 30.97% |
| 3 Year Change | -76.73% |
| 5 Year Change | -84.59% |
| Change since IPO | 90.01% |
Recent News & Updates
Recent updates
Shareholder Returns
| MYD | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -10.0% | 0.8% | 1.2% |
| 1Y | 31.0% | 4.5% | 0.7% |
Return vs Industry: MYD exceeded the German Biotechs industry which returned 4.6% over the past year.
Return vs Market: MYD exceeded the German Market which returned 0.8% over the past year.
Price Volatility
| MYD volatility | |
|---|---|
| MYD Average Weekly Movement | 9.8% |
| Biotechs Industry Average Movement | 7.1% |
| Market Average Movement | 5.4% |
| 10% most volatile stocks in DE Market | 12.8% |
| 10% least volatile stocks in DE Market | 2.7% |
Stable Share Price: MYD's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: MYD's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1991 | 2,700 | Sam Raha | www.myriad.com |
Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women’s health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.
Myriad Genetics, Inc. Fundamentals Summary
| MYD fundamental statistics | |
|---|---|
| Market cap | €438.80m |
| Earnings (TTM) | -€349.23m |
| Revenue (TTM) | €723.97m |
Is MYD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MYD income statement (TTM) | |
|---|---|
| Revenue | US$829.00m |
| Cost of Revenue | US$249.00m |
| Gross Profit | US$580.00m |
| Other Expenses | US$979.90m |
| Earnings | -US$399.90m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
Jul 30, 2026
| Earnings per share (EPS) | -4.23 |
| Gross Margin | 69.96% |
| Net Profit Margin | -48.24% |
| Debt/Equity Ratio | 35.7% |
How did MYD perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/29 11:11 |
| End of Day Share Price | 2026/07/29 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Myriad Genetics, Inc. is covered by 36 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jack Meehan | Barclays |
| Derek Taller | Benchmark Company |
| Michael Ryskin | BofA Global Research |